Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis.

Annals of medicine Pub Date : 2025-12-01 Epub Date: 2025-03-04 DOI:10.1080/07853890.2025.2473627

Zhang Wen, Shuyue Tuo, Qiuju Ran, Jia Yuan, Yong Li, Ying Zhang, Danyan Chang, Chan Li, Shejiao Dai, Jinhai Wang, Xinxing Tantai

{"title":"Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis.","authors":"Zhang Wen, Shuyue Tuo, Qiuju Ran, Jia Yuan, Yong Li, Ying Zhang, Danyan Chang, Chan Li, Shejiao Dai, Jinhai Wang, Xinxing Tantai","doi":"10.1080/07853890.2025.2473627","DOIUrl":null,"url":null,"abstract":"Background: Some adipose-related parameters exhibit distinct prognostic value in patients with cirrhosis. However, the magnitude and direction of the association between individual adipose parameter and mortality in patients with cirrhosis are unclear.Aim: This study aimed to evaluate the association between individual adipose parameter and mortality in patients with cirrhosis using the meta-analysis method.Methods: The PubMed, Embase, Web of Science, China Biological Medicine, WanFang, and China National Knowledge Infrastructure databases were searched from inception through December 15, 2023, to identify eligible studies. The impact of each adipose parameter on mortality was assessed by the pooled unadjusted or adjusted hazard ratio (HR) with 95% confidence intervals (CIs) using the random effects model.Results: A total of 33 studies involving 9626 patients were included in our analysis, with 11 adipose parameters evaluated. The pooled prevalence of sarcopenic obesity (SO) and myosteatosis in patients with cirrhosis was 15.5% and 34.4%, respectively. In adjusted analysis, each unit increase in subcutaneous adipose tissue index (SATI) (HR: 0.99, 95% CI: 0.98-1.00) or muscle attenuation (MA) (HR: 0.94, 95% CI: 0.90-0.98) and each unit decrease in visceral-to-subcutaneous adipose tissue ratio (VSR) (HR: 1.92, 95% CI: 1.45-2.54) showed an independent association with a decreased risk of mortality. However, concurrent myosteatosis (HR: 1.88, 95% CI: 1.48-2.40) or SO (HR: 2.77, 95% CI: 1.95-3.93) significantly increased the risk of mortality in patients with cirrhosis.Conclusion: Decreased SATI or MA, increased VSR, and concurrent myosteatosis or SO were independently associated with a higher risk of mortality in patients with cirrhosis.","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2473627"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884100/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/07853890.2025.2473627","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Some adipose-related parameters exhibit distinct prognostic value in patients with cirrhosis. However, the magnitude and direction of the association between individual adipose parameter and mortality in patients with cirrhosis are unclear.

Aim: This study aimed to evaluate the association between individual adipose parameter and mortality in patients with cirrhosis using the meta-analysis method.

Methods: The PubMed, Embase, Web of Science, China Biological Medicine, WanFang, and China National Knowledge Infrastructure databases were searched from inception through December 15, 2023, to identify eligible studies. The impact of each adipose parameter on mortality was assessed by the pooled unadjusted or adjusted hazard ratio (HR) with 95% confidence intervals (CIs) using the random effects model.

Results: A total of 33 studies involving 9626 patients were included in our analysis, with 11 adipose parameters evaluated. The pooled prevalence of sarcopenic obesity (SO) and myosteatosis in patients with cirrhosis was 15.5% and 34.4%, respectively. In adjusted analysis, each unit increase in subcutaneous adipose tissue index (SATI) (HR: 0.99, 95% CI: 0.98-1.00) or muscle attenuation (MA) (HR: 0.94, 95% CI: 0.90-0.98) and each unit decrease in visceral-to-subcutaneous adipose tissue ratio (VSR) (HR: 1.92, 95% CI: 1.45-2.54) showed an independent association with a decreased risk of mortality. However, concurrent myosteatosis (HR: 1.88, 95% CI: 1.48-2.40) or SO (HR: 2.77, 95% CI: 1.95-3.93) significantly increased the risk of mortality in patients with cirrhosis.

Conclusion: Decreased SATI or MA, increased VSR, and concurrent myosteatosis or SO were independently associated with a higher risk of mortality in patients with cirrhosis.

查看原文本刊更多论文

脂肪相关参数对肝硬化患者死亡率的影响：荟萃分析

背景：一些脂肪相关参数在肝硬化患者中显示出明显的预后价值。然而，肝硬化患者个体脂肪参数与死亡率之间相关性的大小和方向尚不清楚。目的：本研究旨在采用荟萃分析方法评估肝硬化患者个体脂肪参数与死亡率之间的关系。方法：检索PubMed、Embase、Web of Science、中国生物医学、万方和中国国家知识基础设施数据库，从研究开始到2023年12月15日，以确定符合条件的研究。每个脂肪参数对死亡率的影响采用随机效应模型，通过合并未调整或调整的风险比（HR）和95%置信区间（ci）来评估。结果：我们的分析共纳入33项研究，涉及9626例患者，评估了11项脂肪参数。肝硬化患者中肌肉减少性肥胖（SO）和肌骨化病的总患病率分别为15.5%和34.4%。在校正分析中，每单位增加的皮下脂肪组织指数（SATI）（HR: 0.99, 95% CI: 0.98-1.00）或肌肉衰减（MA）（HR: 0.94, 95% CI: 0.90-0.98）和每单位减少的内脏与皮下脂肪组织比（VSR）（HR: 1.92, 95% CI: 1.45-2.54）显示出与死亡风险降低的独立关联。然而，并发肌骨化病（HR: 1.88, 95% CI: 1.48-2.40）或SO （HR: 2.77, 95% CI: 1.95-3.93）显著增加肝硬化患者的死亡风险。结论：肝硬化患者SATI或MA降低、VSR升高、并发肌骨化病或SO与较高的死亡风险独立相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of medicine

自引率

0.00%

发文量